1stOncology™: Cancer Intelligence Service – Page 8543 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

On September 8, 2021 PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, reported that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021 (Press release, PharmaCyte Biotech, SEP 8, 2021, View Source [SID1234587424]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, who will deliver a presentation about PharmaCyte and participate in virtual meetings with institutional investors throughout the conference, said, "We are extremely honored to present at H.C. Wainwright’s 23rd Annual Global Investment Conference. PharmaCyte is forever grateful to H.C. Wainwright for bringing institutional investors to our door so that we could present our story in two separate capital raises that generated about $90 million."

Mr. Waggoner continued, "For the first time in PharmaCyte’s history, we have the opportunity to develop treatments for cancer, diabetes, and malignant ascites fluid without being constrained by finances or the need to raise additional capital. We owe that to H.C. Wainwright and its institutional clients. Presenting at the firm’s Global Investment Conference gives PharmaCyte a platform to continue to tell our story and drive attention to the work we’re doing in developing treatments for hard-to-treat diseases."

Mr. Waggoner’s presentation will provide an overview of the Company’s business. It will be available on-demand through the H.C. Wainwright portal beginning on Monday, September 13, 2021, at 7:00 a.m. EDT.

Webcast link: View Source

An archive of the presentation will be made available for 90 days on the Company’s website under the Media section at View Source

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at: View Source

SCYNEXIS to Participate in Upcoming Investor Conferences

On September 8, 2021 SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, reported that the Company will participate in the following virtual investor conferences in September (Press release, Scynexis, SEP 8, 2021, View Source [SID1234587423]).

Presentation details can be found below:

H.C. Wainwright 23rd Annual Global Investment Conference
Format: On demand presentation and 1-on-1 meetings
Date and Time: Presentation available Monday, September 13 at 7 am ET, 1-on-1 meetings September 13-15
Registration Link
Cantor Fitzgerald Virtual Global Healthcare Conference
Format: Live presentation and 1-on-1 meetings
Date and Time: Thursday, September 30 from 2:40-3:10 pm ET (Track 2)
The presentations and archived webcasts can be found on the SCYNEXIS website at: View Source for 30 days following the event.

Viewpoint Molecular Targeting(R) to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

On September 8, 2021 Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, reported that Frances L. Johnson MD, Chief Executive Officer and Co-Founder of Viewpoint, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021 (Press release, Viewpoint Molecular Targeting, SEP 8, 2021, View Source [SID1234587422]).

Home – Viewpoint
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be available for viewing on-demand beginning Monday, September 13, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the Company’s website (viewpointmt.com). The webcast replay will be archived for 90 days following the event.

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

On September 8, 2021 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, reported that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021 (Press release, AEterna Zentaris, SEP 8, 2021, View Source [SID1234587421]).

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be available for viewing on-demand beginning Monday, September 13, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (www.zentaris.com). The webcast replay will be archived for 90 days following the event.

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

On September 8, 2021 Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, reported that United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted a Market Authorisation Application (MAA) seeking the approval of tebentafusp (IMCgp100) for the treatment of patients with metastatic uveal melanoma (mUM) (Press release, Immunocore, SEP 8, 2021, View Source [SID1234587420]).

Tebentafusp is also being reviewed in the UK under the U.S. Food and Drug Administration’s (FDA) Project Orbis initiative, which enables concurrent review by the health authorities in participating partner countries. As previously announced, the FDA and European Medicines Agency have accepted the Biologics License Application (BLA) and MAA respectively for tebentafusp. In the United States, the BLA was initiated and will be reviewed under the Real-Time Oncology Review (RTOR) pilot program.

The regulatory submissions for tebentafusp are based on data from the randomized Phase 3 IMCgp100-202 clinical trial evaluating tebentafusp in previously untreated metastatic uveal melanoma, a cancer that has historically proven to be frequently insensitive to other immunotherapies. In the final study analysis, tebentafusp demonstrated clinically and statistically significant superior overall survival (OS) benefit as a monotherapy. The primary endpoint was achieved with the OS Hazard Ratio (HR) in the intent-to-treat population favoring tebentafusp, HR=0.51 [95% CI (0.37, 0.71); p< 0.0001] over investigator’s choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine).

Bahija Jallal, Chief Executive Officer of Immunocore, said: "We are delighted that the MHRA has accepted our application for tebentafusp and the FDA has selected tebentafusp for the Project Orbis initiative. As a UK-founded biotech company pioneering the field of TCR therapeutics, we are encouraged with these regulatory milestones that brings us closer to helping people with metastatic uveal melanoma in the UK and abroad. The regulatory agencies recognise the urgent need for an approved treatment specific to mUM, an aggressive form of cancer for which the recommended option for patients is enrolment into a clinical trial."